Literature DB >> 21654556

GITR gene deletion and GITR-FC soluble protein administration inhibit multiple organ failure induced by zymosan.

Maria Galuppo1, Giuseppe Nocentini, Emanuela Mazzon, Simona Ronchetti, Emanuela Esposito, Luisa Riccardi, Rosanna Di Paola, Stefano Bruscoli, Carlo Riccardi, Salvatore Cuzzocrea.   

Abstract

Multiple organ dysfunction syndrome (MODS) is a systemic inflammatory event that can result in organ damage, failure, and high risk of mortality. The aim of this study was to evaluate the possible role of glucocorticoid-induced TNFR-related (GITR) on zymosan-induced MODS. Mice were allocated into one GITR knockout (GITR-KO) and two GITR wild-type (GITR-WT) experimental groups. All the animals were treated with zymosan (500 mg/kg, suspended in saline solution, i.p.), and animals of one GITR-WT group received GITR-Fc (6.25 μg/mouse; 3 h after zymosan injection) by mini-osmotic pump. Moreover, three control groups were performed (one GITR-KO and two GITR-WT experimental groups), administering saline instead of zymosan and treating one of the GITR-WT group with GITR-Fc (6.25 μg/mouse; 3 h after saline injection) by mini-osmotic pump. A number of inflammatory parameters such as edema formation, histological damage, adhesion molecules expression, neutrophil infiltration, proinflammatory cytokines, nitrotyrosine, and iNOS production are significantly reduced in GITR-KO as compared with GITR-WT mice as well as in GITR-WT mice treated with GITR-Fc. We here show that GITR plays a role in the modulation of experimental MODS. In particular, we show that genetic inhibition of GITR expression, in GITR-KO mice, or administration of soluble GITR-Fc receptor in GITR-WT mice, reduces inflammation, organ tissue damage, and mortality. Results, while confirming the proinflammatory role of GITR, extend our observations indicating that GITR plays a role in zymosan-induced inflammation and MODS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21654556     DOI: 10.1097/SHK.0b013e3182262c48

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  5 in total

Review 1.  Modulation of GITR for cancer immunotherapy.

Authors:  David A Schaer; Judith T Murphy; Jedd D Wolchok
Journal:  Curr Opin Immunol       Date:  2012-01-12       Impact factor: 7.486

Review 2.  Pharmacological modulation of GITRL/GITR system: therapeutic perspectives.

Authors:  Giuseppe Nocentini; Simona Ronchetti; Maria Grazia Petrillo; Carlo Riccardi
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 3.  CD8+ T cells: GITR matters.

Authors:  Simona Ronchetti; Giuseppe Nocentini; Maria Grazia Petrillo; Carlo Riccardi
Journal:  ScientificWorldJournal       Date:  2012-04-30

Review 4.  Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells.

Authors:  Simona Ronchetti; Erika Ricci; Maria Grazia Petrillo; Luigi Cari; Graziella Migliorati; Giuseppe Nocentini; Carlo Riccardi
Journal:  J Immunol Res       Date:  2015-04-15       Impact factor: 4.818

5.  Soluble glucocorticoid-induced tumor necrosis factor receptor regulates Helios expression in myasthenia gravis.

Authors:  Yi Li; Shumei Yang; Zhibin Li; Huanyu Meng; Wanling Jin; Huan Yang; Weifan Yin
Journal:  J Transl Med       Date:  2019-05-22       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.